Recent Posts
- Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile
- Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA
- Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.
- Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S.
- Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs
Archives
- No comments have been published yet.
Find us on Facebook
Archives
Recent Posts
- Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile
- Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA
- Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.
- Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S.
- Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs
Recent Tweets
-
If you require Avada theme support bit.ly/2njyfVo check if you are Grandfathered bit.ly/2J3dQw2 |… twitter.com/i/web/status/1…
2 days ago -
@BigPicWeb There is no issue, a reply has been added to the thread. The 100% width template is not meant to display… twitter.com/i/web/status/1…
1 week ago -
"We love the things we love for what they are." Robert Frost pic.twitter.com/wIaNWHDOOf
1 week ago
Recent Comments